Swedbank
RAPP icon

Swedbank’s Rapport Therapeutics RAPP Stock Holding History

Swedbank’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.94M Hold
117,400
– – ﹤0.01% 594
2026
Q2 		$4.89M Buy
117,400
+4,200
+4% +$154K ﹤0.01% 587
2026
Q1 		$3.54M Hold
113,200
– – ﹤0.01% 593
2025
Q4 		$3.43M Buy
+113,200
New +$3.13M ﹤0.01% 599

Other funds holding RAPP

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Catalyst Private Wealth
Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Swedbank's RAPP Position: Q3 2026 in Review

Swedbank held its Rapport Therapeutics (RAPP) position steady in Q3 2026 at 117,400 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #594.

Swedbank first reported a position in RAPP in Q4 2025 and has held it in 4 quarters since. The position peaked at $4.89M in Q2 2026. 24 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Swedbank held 117,400 shares of Rapport Therapeutics worth $3.94M as of Q3 2026.
  • Swedbank left its Rapport Therapeutics share count unchanged in Q3 2026.
  • Rapport Therapeutics made up ﹤0.01% of Swedbank's portfolio in Q3 2026, its #594 holding.
  • Swedbank first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Swedbank's Rapport Therapeutics position peaked at $4.89M in Q2 2026.
  • 24 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Swedbank's 13F filing for Q3 2026, filed 27 Oct 2026.